Anticoagulant management in the cardiovascular setting

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Thrombosis Management

Background:

• Vitamin K antagonists (VKAs) have been oral anticoagulants (OACs) for over 50 years.
• Real-world VKA use is limited by a narrow therapeutic window, drug/food interactions, and need for regular monitoring.
• Suboptimal anticoagulation (under- or over-anticoagulation) affects approximately half of patients on warfarin, increasing risks of thrombosis or bleeding.

Purpose of the Study:

• To review the challenges associated with traditional oral anticoagulants (OACs).
• To introduce the new generation of OACs with improved pharmacological profiles.
• To highlight the benefits of novel OACs in antithrombotic management.

Main Methods:

• Review of existing literature on oral anticoagulants.
• Comparison of pharmacological properties between VKAs and newer OACs.
• Analysis of clinical implications regarding monitoring and drug interactions.

Main Results:

• Warfarin and other VKAs require frequent coagulation monitoring and dose adjustments.
• Newer OACs, including direct Factor Xa inhibitors (rivaroxaban, apixaban) and direct thrombin inhibitors (dabigatran), demonstrate predictable responses.
• These novel agents exhibit fewer drug-drug interactions and do not necessitate routine coagulation monitoring.

Conclusions:

• The limitations of VKAs necessitate alternative anticoagulation strategies.
• Newer OACs represent a significant advancement in antithrombotic therapy.
• Predictable pharmacokinetics and reduced monitoring requirements of novel OACs improve patient management and safety.